Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer

Nuclear assembly factor 1 ribonucleoprotein (NAF1); CDGSH iron sulfur domain 1 (CISD1; mitoNEET)

In vitro and mouse studies suggest inhibiting mitochondrial NAF1 or CISD1 could help treat breast cancer. In three human breast cancer cell lines, NAF1 and CISD1 levels were higher than those in a human epithelial breast cell line. In the cancer cell lines, small hairpin RNA against NAF1 or CISD1 increased mitochondrial iron and reactive oxygen species levels and decreased proliferation compared with scrambled shRNA. In a mouse xenograft model of human breast cancer, shRNA knockdown of NAF1 or CISD1 decreased tumor growth compared with no knockdown. Next steps could include identifying and testing pharmacological inhibitors of NAF1 and CISD1.

SciBX 6(36); doi:10.1038/scibx.2013.988
Published online Sept. 19, 2013

Patent and licensing status unavailable

Sohn, Y.-S. et al. Proc. Natl. Acad. Sci. USA; published online Aug. 19, 2013;
doi:10.1073/pnas.1313198110
Contact: Ron Mittler, University of North Texas, Denton, Texas
e-mail:

ron.mittler@unt.edu
Contact: Rachel Nechushtai, The Hebrew University of Jerusalem, Jerusalem, Israel
e-mail:

rachel@vms.huji.ac.il
Contact: Patricia A. Jennings, University of California, San Diego,
La Jolla, Calif.
e-mail:

pajennings@ucsd.edu
Contact: José N. Onuchic, Rice University, Houston, Texas
e-mail:

jonuchic@rice.edu